MH Case Study

Patient: 45-year-old male, 95 kg, BMI 34 (obese)

PMH: well-controlled HTN on lisinopril, no known neuromuscular disease, no prior anesthesia complications.
Procedure: Emergency open reduction and internal fixation of femur fracture after MVA.
Anesthetic plan: Rapid-sequence induction with succinylcholine 1.5 mg/kg for intubation, maintenance with sevoflurane and O₂/air. Surgery underway.

Intraoperative timeline (minutes after induction):

• T + 8 min: ETCO₂ rises from 36 → 56 mmHg despite unchanged minute ventilation. Tachycardia 120 bpm. Temperature baseline 36.8°C.

• T + 12 min: Generalized jaw/upper-body muscle rigidity (not just trismus). ETCO₂ 68 mmHg; airway pressures increased. BP 150/90 → 170/105.

• T + 15 min: Temp 38.9°C (rapid rise). SpO₂ 98%. Ventilator shows rising peak pressures. Ventilator alarms noted; arterial blood gas drawn.

• T + 18 min: Ventricular ectopy; serum potassium (point of care) 6.0 mEq/L. CK not yet known.

Working diagnosis: Suspected fulminant malignant hyperthermia (MH).

Immediate management — step by step (with rationale & citations)

Goal: recognize MH early, stop triggers, give dantrolene promptly, treat metabolic consequences (hypercarbia, hyperthermia, acidosis, hyperkalemia), protect kidneys, and plan definitive post-crisis care.

1) Call for help & assign roles (OR team)

Action: Announce “malignant hyperthermia” loudly; call anesthesia backup, surgeons, nursing, pharmacy, and get the MH cart/dantrolene. Assign: airway/ventilation, dantrolene reconstitution, cooling, IV/meds, documentation/phone.
Rationale: MH is a rapid, team-based emergency — early coordination shortens time to antidote and reduces complications. (MHAUS/AST recommendations emphasize early team activation and MH trolley availability).

2) Immediately stop all triggering agents

Action: Discontinue volatile anesthetic (turn off sevoflurane), stop succinylcholine (already given), switch to 100% O₂, disconnect vaporizer, change the breathing circuit/CO₂ absorbent if possible, and use a clean anesthesia machine or flush the circuit with high-flow 100% O₂.
Rationale: Volatile anesthetics and succinylcholine are the common triggers; removing the trigger is fundamental to stop ongoing triggering of sarcoplasmic Ca²⁺ release. 

3) Give dantrolene — do the math and give it now

Action & calculation (patient 95 kg): Initial recommended bolus 2.5 mg/kg IV →
2.5 mg/kg × 95 kg = 237.5 mg → round to 238 mg clinically.

• If using Dantrium / common 20 mg vials: 238 mg ÷ 20 mg/vial = 11.9 → 12 vials (240 mg) for initial bolus.

• If using Ryanodex (250 mg vial): 1 vial (250 mg) is enough for the initial bolus and is much faster to prepare.

Repeat dosing: Repeat 2.5 mg/kg boluses PRN until symptoms (ETCO₂, rigidity, temperature, hemodynamics) begin to improve; total cumulative dose may be up to 10 mg/kg for refractory cases. After the acute phase, continue maintenance dosing (see step 7).

Rationale: Early dantrolene halts the pathologic Ca²⁺ release from the sarcoplasmic reticulum, reversing muscle hypermetabolism. Time to dantrolene correlates with outcome. Ryanodex greatly shortens reconstitution time (5 mL vs many vials + large volumes).

4) Hyperventilate with 100% O₂ and manage CO₂/acidosis

Action: Increase minute ventilation (manual ventilation if necessary) to lower PaCO₂/ETCO₂; set FiO₂ 1.0. Obtain arterial blood gas (ABG) immediately. Consider giving sodium bicarbonate if severe metabolic acidosis (e.g., base deficit >-8) per ABG and clinical judgement (example: 1–2 mEq/kg bolus).

Rationale: MH produces massive CO₂ production and metabolic acidosis from muscle hypermetabolism; aggressive ventilation reduces CO₂ and helps prevent arrhythmia and hemodynamic compromise.

5) Active cooling

Action: Start external cooling immediately: ice packs to axillae/groin/neck, cooling blankets, ice lavage if open cavity, and give cold IV crystalloid (4°C if available). Stop cooling when core temp < 38°C and trending down. 

Rationale: Rapid rise in core temperature drives complications (coagulopathy, rhabdomyolysis). Cold IV fluids are an effective initial cooling measure and help preserve renal perfusion in rhabdomyolysis. 

6) Treat hyperkalemia & arrhythmias appropriately; avoid calcium-channel blockers

Action: For K = 6.0 and any ECG changes:

• Stabilize myocardium: IV calcium (calcium chloride 10% 5–10 mL IV or calcium gluconate 10 mL) if ECG changes.

• Shift K intracellularly: insulin 10 units IV + 25 g dextrose, consider nebulized/inhaled albuterol, consider sodium bicarbonate if acidotic.

• Consider urgent dialysis if refractory.

• For arrhythmias, use standard ACLS agents (amiodarone for ventricular arrhythmias). Do NOT use calcium-channel blockers (verapamil/diltiazem) in a patient given dantrolene.

Rationale: Muscle breakdown and cell leak cause hyperkalemia which can precipitate lethal arrhythmias. Important pharmacologic interaction: dantrolene + calcium channel blockers (esp. verapamil/diltiazem) have been associated with severe hyperkalemia and cardiovascular collapse — so avoid CCBs for dysrhythmias in this context.

7) Ongoing dantrolene therapy & monitoring

Action: After initial control, continue dantrolene: commonly recommended 1 mg/kg IV every 4–6 hours for 24–48 hours (or continuous infusion strategies in some centers for severe cases) and/or repeat boluses until clinical improvement. Monitor: ETCO₂, core temperature, ABG, electrolytes, CK, myoglobin, creatinine, urine output (target ≥2 mL/kg/hr during initial management; later at least >1 mL/kg/hr). Consider diuresis and urine alkalinization (bicarbonate) if myoglobinuria/CK rising to protect kidneys. 

Rationale: MH can recrudesce; maintenance dosing reduces relapse risk. Myoglobinuria causes renal failure — high urine output and alkalinization of urine (bicarbonate) reduce myoglobin renal toxicity. Note: some sources recommend ensuring urine output around 2 mL/kg/hr in acute phase because dantrolene vials contain mannitol and aggressive diuresis is beneficial.

8) Labs & supportive care (serial)

Action: Serial ABGs, electrolytes (q15–30 min initially), CK, myoglobin (urine & serum), coags, CBC, renal function. Place Foley for accurate urine output. Prepare for possible transfusion/management of DIC. Transfer to ICU once stabilized. Notify the blood bank if coagulopathy/bleeding. 

Rationale: MH causes rhabdomyolysis → hyperkalemia, metabolic acidosis, DIC, renal failure; continuous monitoring is required to detect/manage complications early.

---

9) If the operation can be stopped, stop it

Action: If feasible and patient unstable, stop surgery promptly (surgeon’s decision). If proceeding is urgent and life- or limb-threatening surgery, balance risks; often best to temporize and stabilize first. 

Rationale: Continuing surgery prolongs exposure to stress and complicates resuscitation; nonessential surgery should be stopped to focus on resuscitation and dantrolene administration. 

10) Post-crisis steps: documentation, testing, counseling

Action:

• Document the event in the chart and anesthesia record as “malignant hyperthermia suspected/treated.”

• Report to your institution’s MH contact/MH registry and to MHAUS.

• Arrange post-op ICU care, plan for continued dantrolene and monitoring for 24–48 hours.

• Advise patient and family about MH susceptibility and need for referral to MH center for diagnostic testing (caffeine-halothane contracture test or genetic testing for RYR1/CACNA1S where available) and provide an alert bracelet/medical alert documentation.

Rationale: MH susceptibility is heritable; patients and first-degree relatives may need testing and must avoid triggering agents in future anesthetics. Proper reporting improves institutional preparedness and contributes to surveillance.

Quick checklist (actionable) — what to do now (in order)

1. Call “MH” and get help + MH cart.

2. Stop volatile agents; administer 100% O₂ and hyperventilate.

3. Give dantrolene NOW (2.5 mg/kg → 240 mg for 95 kg patient; give 12 × 20 mg vials, or 1 × 250 mg Ryanodex vial). Repeat PRN. 

4. Start active cooling and cool IV fluids. 

5. Treat hyperkalemia per ACLS (Ca²⁺ if ECG changes; insulin + glucose; nebulized albuterol; bicarbonate if acidotic). Avoid calcium-channel blockers. 

6. Obtain ABG, labs (electrolytes, CK, myoglobin, coagulation, creatinine) and Foley for urine output. 

1. Continue dantrolene maintenance 1 mg/kg q4–6 hr for 24–48 hr; monitor for recurrence. 

Example calculations & preparation (practical)

• Initial bolus for 95 kg patient at 2.5 mg/kg = 237.5 mg → use 240 mg (12 × 20 mg vials) or 1 × 250 mg Ryanodex vial (much quicker to reconstitute). 

• Maximum suggested cumulative: up to 10 mg/kg if refractory → 10 mg/kg × 95 kg = 950 mg total (≈48 vials of 20 mg Dantrium). MHAUS recommends stocking (and many institutions recommend having on site) at least 36 × 20 mg vials or Ryanodex equivalents.

Pitfalls, pearls & rationales (bite-size)

• Do not delay dantrolene while you wait for ABG or labs, give it as soon as MH strongly suspected. Early administration improves outcomes. 

• Avoid calcium channel blockers for arrhythmia in this setting — the combination with dantrolene can cause fatal hyperkalemia/cardiovascular collapse. Use amiodarone or standard ACLS alternatives instead.

• Ryanodex is much faster to prepare (single 250 mg vial reconstituted with 5 mL) vs Dantrium (many 20 mg vials needing large volumes); stocking decisions matter for response time.

• MH can be delayed (even hours after exposure) — monitor patients carefully post-op if any exposure occurred.

Sources (key references for clinicians)

• Malignant Hyperthermia Association of the United States (MHAUS): managing a crisis, recommendations, MH cart guidance.

• StatPearls / NCBI: malignant hyperthermia overview and treatment summary.

• European MH Group (EMHG) recommendations (2024) — dosing and practical guidance.

• EMCRIT/IBCC MH guide — practical clinical pearls on recognition and ventilation/cooling.

• Dantrolene product/technical notes (Ryanodex vs Dantrium): preparation and dosing considerations. 

If you want, I can next:

• Turn this into a timed simulation checklist you can print for OR teams.

• Produce a single-page MH crisis card (with the dosing math auto-filled for a chosen weight).

• Or run a variant of the case (e.g., pediatric, without succinylcholine, or delayed postoperative MH) — tell me which and I’ll generate it with stepwise reasoning.